JPH0471520B2 - - Google Patents

Info

Publication number
JPH0471520B2
JPH0471520B2 JP2267500A JP26750090A JPH0471520B2 JP H0471520 B2 JPH0471520 B2 JP H0471520B2 JP 2267500 A JP2267500 A JP 2267500A JP 26750090 A JP26750090 A JP 26750090A JP H0471520 B2 JPH0471520 B2 JP H0471520B2
Authority
JP
Japan
Prior art keywords
cells
human
hybridoma
cell line
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP2267500A
Other languages
English (en)
Japanese (ja)
Other versions
JPH03236794A (ja
Inventor
Rarusu Oeshutoberuku Gunnaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JPH03236794A publication Critical patent/JPH03236794A/ja
Publication of JPH0471520B2 publication Critical patent/JPH0471520B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/166—Animal cells resulting from interspecies fusion
    • C07K16/108—

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2267500A 1982-01-22 1990-10-03 ヒトモノクローン抗体の製造法 Granted JPH03236794A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH409/82A CH652145A5 (de) 1982-01-22 1982-01-22 Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
CH409/82 1982-01-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP58009241A Division JPS58128323A (ja) 1982-01-22 1983-01-21 ヒトモノクロ−ン抗体の製造法

Publications (2)

Publication Number Publication Date
JPH03236794A JPH03236794A (ja) 1991-10-22
JPH0471520B2 true JPH0471520B2 (OSRAM) 1992-11-13

Family

ID=4186382

Family Applications (3)

Application Number Title Priority Date Filing Date
JP58009241A Granted JPS58128323A (ja) 1982-01-22 1983-01-21 ヒトモノクロ−ン抗体の製造法
JP2267500A Granted JPH03236794A (ja) 1982-01-22 1990-10-03 ヒトモノクローン抗体の製造法
JP3157731A Expired - Lifetime JPH0789909B2 (ja) 1982-01-22 1991-05-30 ハイブリドーマセルラインの製造法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP58009241A Granted JPS58128323A (ja) 1982-01-22 1983-01-21 ヒトモノクロ−ン抗体の製造法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP3157731A Expired - Lifetime JPH0789909B2 (ja) 1982-01-22 1991-05-30 ハイブリドーマセルラインの製造法

Country Status (17)

Country Link
US (1) US4634664A (OSRAM)
JP (3) JPS58128323A (OSRAM)
AT (1) AT388932B (OSRAM)
CH (1) CH652145A5 (OSRAM)
CY (1) CY1488A (OSRAM)
DE (1) DE3301249A1 (OSRAM)
DK (1) DK23183A (OSRAM)
FI (1) FI83538C (OSRAM)
FR (1) FR2522679B1 (OSRAM)
GB (1) GB2113715B (OSRAM)
HK (1) HK52589A (OSRAM)
IL (1) IL67721A (OSRAM)
IT (1) IT1160468B (OSRAM)
KE (1) KE3884A (OSRAM)
MY (1) MY8700169A (OSRAM)
SE (1) SE502344C2 (OSRAM)
SG (1) SG28189G (OSRAM)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
EP0148644A3 (en) * 1984-01-06 1987-06-03 The Board Of Trustees Of The Leland Stanford Junior University A novel fusion partner and its products
US4764465A (en) * 1984-04-26 1988-08-16 Cetus Corporation Human monoclonal antibody against group A red blood cells
JPS6187630A (ja) * 1984-10-08 1986-05-06 Teijin Ltd 単純ヘルペスウイルスに対するヒトモノクロ−ナル抗体及びその製造法
WO1986002092A1 (fr) * 1984-09-28 1986-04-10 Teijin Limited Hybridome homme-souris produisant un anticorps humain antiviral, procede de preparation et anticorps monoclonal humain antiviral
US4693975A (en) * 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
JPS61155398A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 抗緑膿菌ヒトモノクロ−ナル抗体及びその製造法並びにそれを有効成分とする治療剤
USH1198H (en) 1985-04-26 1993-06-01 Cetus Corporation Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
CH670098B (OSRAM) * 1985-05-23 1989-05-12
JPH0720885B2 (ja) * 1985-09-27 1995-03-08 帝人株式会社 単純ヘルペスウイルス感染症の予防又は治療剤
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
AU7281787A (en) * 1986-04-01 1987-10-20 Genelabs Incorporated Immortalized cells which produce tissue-specific products
EP0261233A4 (en) * 1986-04-01 1988-08-29 Genelabs Inc IMMORTALIZED TISSUE CELLS WITH VIRAL SPECIFICITY.
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5646041A (en) * 1987-02-12 1997-07-08 Harfeldt; Elisabeth Monoclonal antibody to herpes simplex virus and cell line producing same
US5001065A (en) * 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH01101896A (ja) * 1987-10-14 1989-04-19 Teijin Ltd カンジダに対するヒト・モノクローナル抗体とその製造法
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
IT1226477B (it) * 1988-07-04 1991-01-16 Genetik Mab S R L Linee cellulari n omas quale un mezzo per immortalare cellule produttrici di sostanze di qualunque specie animale.
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2535455B2 (ja) * 1991-02-07 1996-09-18 帝人株式会社 サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ
FI940144L (fi) * 1991-07-15 1994-01-12 Wellcome Found Vasta-aineiden tuotanto
JPH05276984A (ja) * 1991-09-05 1993-10-26 Teijin Ltd カンジダに対するヒト・モノクローナル抗体を産生するハイブリドーマ
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
CA2116246A1 (en) * 1992-06-26 1994-01-06 Roland Beliard Human monoclonal anti-rhesus (d) antibodies and cell lines producing same
EP0583980A1 (en) * 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
HUT72546A (en) * 1992-11-06 1996-05-28 Sandoz Ag Production of human monoclonal antibodies active against hepatitis b surface antigen
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
EP0966533B1 (en) 1997-02-07 2009-09-16 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Activity dependent neurotrophic factor iii (adnf iii)
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU1456101A (en) * 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA03009566A (es) 2001-04-19 2004-12-06 Scripps Research Inst Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales.
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20030082188A1 (en) * 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
AU2003304411A1 (en) 2002-08-01 2005-03-07 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
HUE035044T2 (en) 2003-05-19 2018-05-02 Prothena Biosciences Ltd Truncated fragments of alpha-synuclein in Lewy-body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2392923B1 (en) 2003-06-18 2014-05-21 The Scripps Research Institute Method of producing proteins comprising unnatural amino acid
ES2393492T3 (es) 2004-05-25 2012-12-21 Medimmune, Llc Variantes de hemaglutinina y neuraminidasa de influenza
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
CN101146554B (zh) 2005-01-27 2012-10-10 加州大学评议会 中和肉毒杆菌神经毒素的治疗性单克隆抗体
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2009094B1 (en) 2006-04-13 2010-06-09 Medical and Biological Laboratories Co., Ltd. Fusion partner cells
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ES2374845T3 (es) * 2006-05-22 2012-02-22 Xbiotech, Inc Tratamiento de cáncer con anticuerpos anti-il-1.
JP2009543579A (ja) 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8440185B2 (en) * 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
AU2007339773B2 (en) * 2006-12-27 2011-03-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
ES2570182T3 (es) 2007-02-23 2016-05-17 Prothena Biosciences Ltd Prevención y tratamiento de la enfermedad sinucleinopática y amiloidogénica
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2185718B1 (en) 2007-08-03 2017-10-04 MUSC Foundation For Research Development Human monoclonal antibodies and methods for producing the same
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2185196B1 (en) 2007-08-27 2014-06-11 Longhorn Vaccines & Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
EP2195654A1 (en) 2007-10-05 2010-06-16 National Institute for Bioprocessing Research and Training Limited Glycosylation markers for pancreatitis, sepsis and pancreatic cancer
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US20090169549A1 (en) * 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
EP3085773B1 (en) * 2008-05-30 2020-03-18 XBiotech, Inc Uses of il-1 alpha antibodies
JPWO2009148150A1 (ja) * 2008-06-06 2011-11-04 国立大学法人富山大学 インフルエンザウィルス検出用デバイス
JP2011527581A (ja) 2008-07-11 2011-11-04 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
US8242074B2 (en) * 2008-09-12 2012-08-14 Xbiotech, Inc. Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
RU2535970C2 (ru) 2009-02-12 2014-12-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейраминидазы гриппа
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
CN102666581A (zh) 2009-08-31 2012-09-12 艾普利穆恩公司 用于抑制移植物排斥的方法和组合物
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
KR102314003B1 (ko) 2010-08-23 2021-10-19 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
SI3461847T1 (sl) 2010-12-06 2021-03-31 Seagen Inc. Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka
KR102326482B1 (ko) 2011-04-01 2021-11-17 엑스바이오테크 인코포레이티드 피부과학적 병리의 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
HK1211960A1 (en) 2012-10-04 2016-06-03 Xbiotech, Inc Treating vascular disease and complications thereof
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
EP3016683B1 (en) 2013-07-05 2020-06-24 University of Washington through its Center for Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
AU2016255768B2 (en) 2015-04-29 2022-03-10 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
BR112018067458A2 (pt) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MY197413A (en) 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP2019522800A (ja) 2016-07-06 2019-08-15 プロセナ バイオサイエンシーズ リミテッド 総及びＳ１２９リン酸化α−シヌクレインの検出アッセイ
SG11201907159SA (en) 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
WO2018222675A1 (en) 2017-05-30 2018-12-06 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
BR112020001255A2 (pt) 2017-07-21 2020-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services composições imunogênicas de neisseria meningitidis
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
WO2019086331A2 (en) 2017-11-02 2019-05-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
US20220023348A1 (en) 2018-11-28 2022-01-27 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
TW202045206A (zh) 2019-02-27 2020-12-16 美商健生生物科技公司 抗體調配物
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3164168A1 (en) 2020-01-08 2021-07-15 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
WO2021211924A1 (en) 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of atopic dermatitis
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
IL299329A (en) 2020-06-24 2023-02-01 Prothena Biosciences Ltd Antibodies recognizing sortilin
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
IE20210235A1 (en) 2020-10-20 2023-08-16 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
US20240238427A1 (en) 2021-04-14 2024-07-18 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757169A1 (de) * 1977-12-22 1979-07-05 Hoechst Ag Verfahren zur gewinnung insulin produzierender tierischer zellen
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
GB2079313A (en) * 1980-07-07 1982-01-20 Nat Res Dev Improvements in or relating to rat myeloma cell lines
JPS57502090A (OSRAM) * 1980-07-18 1982-11-25
JPS586475B2 (ja) * 1980-08-23 1983-02-04 株式会社 林原生物化学研究所 ヒト絨毛性性腺刺激ホルモンの製造方法
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
JPS585671B2 (ja) * 1980-08-27 1983-02-01 株式会社 林原生物化学研究所 ヒト卵胞刺激ホルモンの製造方法
JPS5743696A (en) * 1980-08-27 1982-03-11 Hayashibara Biochem Lab Inc Preparation of human luteinizing hormone
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4529694A (en) * 1982-04-16 1985-07-16 The Children's Medical Center Corporation Cell fusion

Also Published As

Publication number Publication date
DK23183D0 (da) 1983-01-20
CH652145A5 (de) 1985-10-31
IT1160468B (it) 1987-03-11
GB2113715B (en) 1986-06-04
JPH0789909B2 (ja) 1995-10-04
HK52589A (en) 1989-07-07
GB8301384D0 (en) 1983-02-23
IT8319234A0 (it) 1983-01-21
DE3301249A1 (de) 1983-09-22
ATA19583A (de) 1989-02-15
FI830190L (fi) 1983-07-23
FI830190A0 (fi) 1983-01-20
IL67721A0 (en) 1983-05-15
JPS58128323A (ja) 1983-07-30
AT388932B (de) 1989-09-25
IL67721A (en) 1986-04-29
FR2522679B1 (fr) 1986-05-09
SE8300290D0 (sv) 1983-01-20
MY8700169A (en) 1987-12-31
GB2113715A (en) 1983-08-10
JPH0365148B2 (OSRAM) 1991-10-09
JPH0690753A (ja) 1994-04-05
US4634664A (en) 1987-01-06
SE502344C2 (sv) 1995-10-09
FR2522679A1 (fr) 1983-09-09
CY1488A (en) 1989-12-08
FI83538C (fi) 1991-07-25
KE3884A (en) 1989-08-11
SG28189G (en) 1989-08-11
JPH03236794A (ja) 1991-10-22
SE8300290L (sv) 1983-07-23
DE3301249C2 (OSRAM) 1990-04-05
DK23183A (da) 1983-07-23
FI83538B (fi) 1991-04-15

Similar Documents

Publication Publication Date Title
JPH0471520B2 (OSRAM)
EP0014519B1 (en) Cell lines, process for preparing them and process for producing antibodies
EP0182467B1 (en) Human hybridoma fusion partner for production of human monoclonal antibodies
US4464465A (en) Cell-driven viral transfer in eukaryotes
US4594325A (en) High fusion frequency fusible lymphoblastoid cell line
EP0583980A1 (en) Method for generating monoclonal antibodies from rabbits
JPS6317688A (ja) ヒト―ヒトハイブリドーマの製造法
US5114847A (en) Process for the production of permanently culturable animal and human cell lines and the use thereof
CA1214123A (en) Cell lines for use in the preparation of hybridoma cells
US4752582A (en) Monoclonal antibodies to human glycophorin A and cell lines for the production thereof
WO1983001739A1 (en) Monoclonal antibodies against brugia malayi
EP0157574B1 (en) Antitetanic antibody producing human-human hybridoma and method of producing the same
Van Meel et al. Human and chimpanzee monoclonal antibodies
Diamond et al. Monoclonal antibodies
JP3043023B2 (ja) ハイブリドーマ
Schönherr et al. Antibody engineering, a strategy for the development of monoclonal antibodies
AU603985B2 (en) Non-human primate monoclonal antibodies and triomas producing them
Cole Monoclonal antibodies
JPS6239999B2 (OSRAM)
Shoenfeld et al. The Production of Monoclonal Antibodies by Human—Human Hybridomas: Their Application to Studies of Autoimmune Diseases
JPH0679553B2 (ja) 新規な雑種細胞
JPH08224079A (ja) ガン関連抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
JPH0570437B2 (OSRAM)